HomeCompareNMTR vs KMB

NMTR vs KMB: Dividend Comparison 2026

NMTR yields 2770.08% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NMTR wins by $212938372920.86M in total portfolio value
10 years
NMTR
NMTR
● Live price
2770.08%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$212938372920.91M
Annual income
$198,819,380,806,317,020.00
Full NMTR calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — NMTR vs KMB

📍 NMTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNMTRKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NMTR + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NMTR pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NMTR
Annual income on $10K today (after 15% tax)
$235,457.06/yr
After 10yr DRIP, annual income (after tax)
$168,996,473,685,369,470.00/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, NMTR beats the other by $168,996,473,685,365,020.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NMTR + KMB for your $10,000?

NMTR: 50%KMB: 50%
100% KMB50/50100% NMTR
Portfolio after 10yr
$106469186460.48M
Annual income
$99,409,690,403,161,120.00/yr
Blended yield
93.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

NMTR
No analyst data
Altman Z
-49.9
Piotroski
2/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NMTR buys
0
KMB buys
0
No recent congressional trades found for NMTR or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNMTRKMB
Forward yield2770.08%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$212938372920.91M$45.9K
Annual income after 10y$198,819,380,806,317,020.00$5,222.34
Total dividends collected$211957883813.74M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: NMTR vs KMB ($10,000, DRIP)

YearNMTR PortfolioNMTR Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$287,708$277,008.31$11,314$614.45+$276.4KNMTR
2$7,756,221$7,448,373.17$12,867$760.19+$7.74MNMTR
3$195,960,759$187,661,602.67$14,713$945.27+$195.95MNMTR
4$4,640,768,087$4,431,090,074.46$16,924$1,181.90+$4640.75MNMTR
5$103,038,191,206$98,072,569,353.09$19,596$1,486.64+$103038.17MNMTR
6$2,145,287,049,877$2,035,036,185,286.86$22,850$1,882.16+$2145287.03MNMTR
7$41,893,666,105,695$39,598,208,962,326.13$26,849$2,399.80+$41893666.08MNMTR
8$767,520,675,750,287$722,694,453,017,193.00$31,812$3,083.36+$767520675.72MNMTR
9$13,195,319,733,262,706$12,374,072,610,209,900.00$38,033$3,994.72+$13195319733.22MNMTR
10$212,938,372,920,908,130$198,819,380,806,317,020.00$45,918$5,222.34+$212938372920.86MNMTR

NMTR vs KMB: Complete Analysis 2026

NMTRStock

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Full NMTR Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this NMTR vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NMTR vs SCHDNMTR vs JEPINMTR vs ONMTR vs KONMTR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.